Oncotarget

Research Papers:

Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis

Berenice Ortiz _, Julie R. White, Wei H. Wu and Timothy A. Chan

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:6976-6982. https://doi.org/10.18632/oncotarget.2106

Metrics: PDF 2701 views  |   HTML 3009 views  |   ?  


Abstract

Berenice Ortiz1,2, Julie R. White3, Wei H. Wu2 and Timothy A. Chan2,4,5

1 Gerstner Sloan-Kettering Graduate School, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

2 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

3 The Tri-Institutional Laboratory of Comparative Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

4 Dept. of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

5 Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence:

Timothy A. Chan, email:

Keywords: PTPRD, CDKN2A

Received: May 9, 2014 Accepted: June 12, 2014 Published: June 14, 2014

Abstract

PTPRD encodes the protein tyrosine phosphatase receptor type D and is frequently inactivated across many human cancers. Despite its frequent inactivation, it is unknown whether loss of PTPRD promotes tumorigenesis in vivo. PTPRD is located on chromosome 9p, as is CDKN2A, and the two loci are frequently deleted together. Here, we show that co-deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Interestingly,heterozygous loss of Ptprd was sufficient to promote tumorigenesis in our model, suggesting that Ptprd may be a haploinsufficient tumor suppressor. The loss of Ptprd resulted in changes to the tumor spectrum in mice and increased the frequency of lymphomas. In total, we reveal that Ptprd is a tumor suppressor that can promote tumorigenesis in concert with Cdkn2a loss.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2106